__timestamp | Geron Corporation | Grifols, S.A. |
---|---|---|
Wednesday, January 1, 2014 | 16758000 | 660772000 |
Thursday, January 1, 2015 | 17793000 | 736435000 |
Friday, January 1, 2016 | 18761000 | 775266000 |
Sunday, January 1, 2017 | 19287000 | 860348000 |
Monday, January 1, 2018 | 18707000 | 814775000 |
Tuesday, January 1, 2019 | 20893000 | 942821000 |
Wednesday, January 1, 2020 | 25678000 | 985616000 |
Friday, January 1, 2021 | 29665000 | 1061508000 |
Saturday, January 1, 2022 | 43628000 | 1190423000 |
Sunday, January 1, 2023 | 69135000 | 1254234000 |
In pursuit of knowledge
In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. Over the past decade, Grifols, S.A. and Geron Corporation have shown contrasting trends in their SG&A expenditures.
From 2014 to 2023, Grifols, S.A. has seen a consistent increase in SG&A expenses, rising by approximately 90%. This growth reflects the company's expanding operations and strategic investments in administrative capabilities.
In contrast, Geron Corporation's SG&A expenses have surged by over 300% during the same period. This sharp increase, particularly notable in the last few years, suggests a significant shift in the company's operational strategy, possibly indicating aggressive expansion or restructuring efforts.
These trends highlight the diverse strategies companies employ to manage their operational costs, offering valuable insights for investors and analysts alike.
Comparing SG&A Expenses: AbbVie Inc. vs Grifols, S.A. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Geron Corporation
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation